Letters to the Editor

Ruxolitinib in treatment-naive or corticosteroid-refractory pediatric patients with chronic graft-versus-host disease: final analysis of the phase 2 REACH5 trial

Department of Pediatric Hematology/Oncology and Cell and Gene Therapy, IRCCS Bambino Gesù Children's Hospital, Catholic University of the Sacred Heart, Rome
Division of Pediatric Hematology and Oncology and Stem Cell Transplantation, Department of Pediatrics, Acıbadem Adana Hospital, Adana, Türkiye
Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute, Seoul National University Children's Hospital, Seoul
Department of Hematology/ Oncology, Saitama Children's Medical Center, Saitama
Department of Pediatrics, Nagoya University Graduate School of Medicine, Nagoya
Paediatric Hematology Oncology, Akdeniz University School of Medicine, Antalya, Türkiye
GRAACC, São Paulo
Division of Hematology/Oncology, The Hospital for Sick Children, The University of Toronto, Toronto, Ontario
Mazumdar Shaw Medical Center, Narayana Health City, Bangalore
Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul
Department of Hematology/Oncology/Immunology, Gene Therapy, and Stem Cell Transplantation, University Children's Hospital Zürich, Eleonore Foundation and Children's Research Center, Zurich
Department of Pediatrics, National Taiwan University Hospital, Taipei
Novartis Pharma AG, Basel
Novartis Pharma S.A.S, Paris
Novartis Ireland Limited, Dublin
Novartis Pharma AG, Basel
Division of Pediatric Hematology and Oncology and Stem Cell Transplantation, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, Barcelona
Haematologica Early view Feb 19, 2026 https://doi.org/10.3324/haematol.2025.300144